RXO, Inc. (RXO) — Fair Value Analysis
Base-case fair value (P50): $18.86 · Current price: $23.52 · Verdict: Overvalued
The Verdict on RXO
Our Monte Carlo simulations indicate that RXO is Fairly Valued at its current market price. With RXO trading at $23.52, our median fair value (P50) stands at $18.86, implying a -19.8% difference from the current price. This suggests the market price is largely aligned with our comprehensive valuation model's outlook, neither presenting a compelling discount nor a significant premium at this juncture. Investors looking for substantial mispricing may find RXO's current valuation less appealing, given its proximity to the P50 fair value.
How RXO stacks up against peers
Despite being Fairly Valued by our core model, RXO's operational and financial health is categorized as weak compared to its sector peers. This qualitative tier reflects underlying challenges or inefficiencies that, while not currently driving a significant undervaluation, could cap upside potential or exacerbate downside scenarios. While the quantitative fair value sits close to $23.52, this weak quality tier highlights areas where RXO might lag its competition, suggesting a higher degree of risk for long-term investors if these issues persist.
What this means for investors
The assessment that RXO is Fairly Valued, with a median fair value of $18.86 against its current trading price of $23.52, suggests that the market has largely priced in available information. The -19.8% difference indicates minimal immediate arbitrage opportunity. For investors, the weak quality tier is a crucial consideration, implying that even at a seemingly fair price, the company's relative health could pose headwinds. While a deep discount isn't present, a bull case would depend on significant operational improvements, while a downside scenario could be more pronounced given the current weak quality standing. To see the full bear/bull distribution and track RXO's fair value as new fundamentals are released, sign up for a free FairCurve account.
Frequently Asked Questions
Is RXO overvalued or undervalued right now?
RXO is currently assessed as Fairly Valued. Our median fair value (P50) is $18.86, which is very close to its current price of $23.52.
What is the bear case and bull case for RXO?
Our full Monte Carlo distribution, including the bear case (P10) and bull case (P90) target prices, along with the probability of upside, is exclusively available to FairCurve account holders. We do not provide specific dollar values here.
How does FairCurve calculate RXO's fair value?
FairCurve calculates RXO's fair value using sophisticated Monte Carlo simulations, running thousands of forward-looking scenarios to determine a probabilistic range of potential valuations.
How can I track RXO's fair value as it changes?
You can add RXO to your free FairCurve watchlist to receive daily fair-value updates and instant re-valuation notices whenever new earnings or significant fundamental data are released.